|
2026 Journal Article Beyond Bloodstream Infection: The Potential for Hierarchical Composite Endpoints in Vascular Access ResearchMellander, Carl, Martin, Andrew J, Langan, Gaurav, Seifert, Stefanie, Hammarskjöld, Fredrik, Taxbro, Knut and Rickard, Claire M (2026). Beyond Bloodstream Infection: The Potential for Hierarchical Composite Endpoints in Vascular Access Research. Clinical Infectious Diseases ciag276. doi: 10.1093/cid/ciag276 |
|
2026 Journal Article Predictive value of early PSMA upregulation for the response to enzalutamide ± <SUP>177</SUP>Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer: substudy of the randomized, phase 2 ENZA-p trialEmmett, Louise, Swiha, Mina, Papa, Nathan, Subramaniam, Shalini, Crumbaker, Megan, Joshua, Anthony, Nguyen, Andrew, Weickhardt, Andrew, Lee, Sze-Ting, Ng, Siobhan, Francis, Roslyn, Goh, Jeffrey, Pattison, David, Pathmanandavel, Sarennya, Hope, Thomas, Ayati, Narjess, Hofman, Michael, Sandhu, Shahneen, Niu, Claire, Martin, Andrew, Thomas, Hayley, Stockler, Martin and Davis, Ian (2026). Predictive value of early PSMA upregulation for the response to enzalutamide ± 177Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer: substudy of the randomized, phase 2 ENZA-p trial. Nature Cancer, 7 (4), 622-630. doi: 10.1038/s43018-026-01140-3 |
|
2026 Journal Article <sup>177</sup> Lu-PSMA-617 SPECT/CT for Early Prediction of Overall Survival in Participants with Metastatic Castration-Resistant Prostate CancerAyati, Narjess, Papa, Nathan, Crumbaker, Megan, Subramaniam, Shalini, Joshua, Anthony M., Alipour, Ramin, Iravani, Amir, Askari, Emran, Khan, Sobia, Yadav, Surekha, Eiber, Matthias, Weickhardt, Andrew, Lee, Sze-Ting, Ng, Siobhan, Francis, Roslyn J., Goh, Jeffrey C., Pattison, David A., Tan, Thean Hsiang, Kirkwood, Ian D., Nguyen, Andrew, Hofman, Michael S., Sandhu, Shahneen, Hioki, Takanori, van Oorschodt, Julian C. J., Devitt, Katrina, Willowson, Kathy, Sharma, Shikha, Stancu, Alexandru, Chauvie, Stephane ... on behalf of the Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group (2026). 177 Lu-PSMA-617 SPECT/CT for Early Prediction of Overall Survival in Participants with Metastatic Castration-Resistant Prostate Cancer. Radiology, 319 (1) e252672. doi: 10.1148/radiol.252672 |
|
2026 Conference Publication How is implementation science used in hybrid effectiveness-implementation randomised controlled trials? A state-of-the-art review of early adoptersHickman, Ingrid, Liu, Mark, Comber, Elouise, Costa, Nathalia, Trott, Mike, Roberts, Natasha, Martin, Andrew and Foster, Nadine (2026). How is implementation science used in hybrid effectiveness-implementation randomised controlled trials? A state-of-the-art review of early adopters. LONDON: BMC. |
|
2026 Conference Publication BCG plus mitomycin (BCG plus MM) versus BCG-alone as adjuvant intravesical therapy for high-risk, Non-Muscle-Invasive Bladder Cancer (NMIBC): Effects on urinary symptoms and other aspects of Health-Related Quality of Life (HRQL) in a randomised trial (BCGMM, ANZUP 1301)Hayne, D., Zhang, A. Y., Thomas, H., Krieger, L., Ischia, J., Anderson, P., Srivastav, R., Green, W., Grummet, J., Bastick, P., Beardsley, E., Blatt, A., Patel, M., Mitterdorfer, A., Roberts, M., Sengupta, S., Winter, M., Cheung, L., Hawks, C., Martin, A., Mccombie, S. P., Redfern, A. D., Davis, I. and Stockler, M. R. (2026). BCG plus mitomycin (BCG plus MM) versus BCG-alone as adjuvant intravesical therapy for high-risk, Non-Muscle-Invasive Bladder Cancer (NMIBC): Effects on urinary symptoms and other aspects of Health-Related Quality of Life (HRQL) in a randomised trial (BCGMM, ANZUP 1301). AMSTERDAM: ELSEVIER. |
|
2026 Journal Article Clonal hematopoiesis after 177Lu-PSMA-617 radioligand therapy in prostate cancerMunzur, Aslı D., Herberts, Cameron, Kwan, Edmond M., Emmett, Louise, Sandhu, Shahneen, Buteau, James P., Iravani, Amir, Joshua, Anthony M., Francis, Roslyn J., Lee, Sze-Ting, Scott, Andrew M., Martin, Andrew J., Stockler, Martin R., Zhang, Alison Y., Williams, Scott G., Bernales, Cecily Q., Donnellan, Gráinne, Koudjanian, Melissa, Parekh, Karan, Bacon, Jack V. W., Karsan, Aly, Azad, Arun A., Davis, Ian D., Hofman, Michael S. and Wyatt, Alexander W. (2026). Clonal hematopoiesis after 177Lu-PSMA-617 radioligand therapy in prostate cancer. Clinical Cancer Research, OF1-OF9. doi: 10.1158/1078-0432.ccr-25-4001 |
|
2026 Journal Article Target trial emulation of early docetaxel and enzalutamide for metastatic hormone-sensitive prostate cancerSoon, Yu Yang, Marschner, Ian C., Schou, I. Manjula, Sweeney, Christopher J., Davis, Ian D., Stockler, Martin R. and Martin, Andrew J. (2026). Target trial emulation of early docetaxel and enzalutamide for metastatic hormone-sensitive prostate cancer. BJU International, 137 (1) bju.70065, 173-180. doi: 10.1111/bju.70065 |
|
2026 Journal Article Bacillus Calmette-Guérin Plus Mitomycin Versus Bacillus Calmette-Guérin Alone for Bacillus Calmette-Guérin–naïve Non–muscle-invasive Bladder Cancer: A Randomised Phase 3 Trial (ANZUP 1301)Hayne, Dickon, Zhang, Alison Y., Thomas, Hayley, Krieger, Laurence, Ischia, Joseph, Anderson, Paul, Srivastav, Ratnesh K., Green, William, Grummet, Jeremy, Bastick, Patricia A., Beardsley, Emma K., Blatt, Alison, Patel, Manish, Chan, Lewis, Mitterdorfer, Andrew, Roberts, Matthew, Sengupta, Shomik, Winter, Matthew, Marx, Gavin, Bishop, Conrad, Cheung, Leanna, Hawks, Cynthia, Martin, Andrew, McCombie, Steve P., Redfern, Andrew D., Davis, Ian D. and Stockler, Martin R. (2026). Bacillus Calmette-Guérin Plus Mitomycin Versus Bacillus Calmette-Guérin Alone for Bacillus Calmette-Guérin–naïve Non–muscle-invasive Bladder Cancer: A Randomised Phase 3 Trial (ANZUP 1301). European Urology. doi: 10.1016/j.eururo.2026.01.009 |
|
2025 Journal Article Evaluating clinician sustainment of a Mediterranean‐style dietary pattern approach in routine care for coronary heart disease and type 2 diabetes utilizing Normalization MeAsure Development (NoMAD) instrumentMayr, Hannah L., Murray, Eryn, Maher, Patrick, Hayes, Lisa, Wang, William Y. S., Kelly, Jaimon T., Palmer, Michelle, Martin, Andrew and Hickman, Ingrid J. (2025). Evaluating clinician sustainment of a Mediterranean‐style dietary pattern approach in routine care for coronary heart disease and type 2 diabetes utilizing Normalization MeAsure Development (NoMAD) instrument. Nutrition in Clinical Practice, 40 (6) ncp.70055, 1552-1569. doi: 10.1002/ncp.70055 |
|
2025 Conference Publication Addition of early docetaxel to enzalutamide for metastatic hormone-sensitive prostate cancer: a trial emulation approach based on the ENZAMET trialSoon, Y. Y., Marschner, I. C., Schou, M., Sweeney, C., Davis, I. D., Stockler, M. R. and Martin, A. J. (2025). Addition of early docetaxel to enzalutamide for metastatic hormone-sensitive prostate cancer: a trial emulation approach based on the ENZAMET trial. AMSTERDAM: ELSEVIER. doi: 10.1016/j.annonc.2025.08.3037 |
|
2025 Journal Article Health-related quality-of-life outcomes with regorafenib in advanced gastric and esophagogastric junction cancer: results from the INTEGRATE trialsMartin, Andrew J., Soon, Yu Yang, Sjoquist, Katrin Marie, Pavlakis, Nick, Goldstein, David, Shitara, Kohei and Simes, John R. (2025). Health-related quality-of-life outcomes with regorafenib in advanced gastric and esophagogastric junction cancer: results from the INTEGRATE trials. Gastric Cancer, 28 (6), 1252-1259. doi: 10.1007/s10120-025-01670-2 |
|
2025 Conference Publication PCPro, plasma lipid biomarker, in metastatic hormone-sensitive prostate cancer (mHSPC): from research to clinical implementation in the ENZAMET trial (ANZUP 1304)Mellor, R., Fitzpatrick, M., Scheinberg, T., Kim, R. M., Bonnitcha, P., Sullivan, D., Lin, H-m., Davis, I. D., Martin, A. J., Meikle, P., Joshua, A. M., Mcjannett, M., Subhash, V., Yip, S., North, S., Mcdermott, R., Chi, K. N., Stockler, M. R., Sweeney, C. and Horvath, L. G. (2025). PCPro, plasma lipid biomarker, in metastatic hormone-sensitive prostate cancer (mHSPC): from research to clinical implementation in the ENZAMET trial (ANZUP 1304). AMSTERDAM: ELSEVIER. doi: 10.1016/j.annonc.2025.08.3098 |
|
2025 Journal Article Association of the circulating lipid panel, PCPro, with clinical outcomes in metastatic hormone-sensitive prostate cancer: post-hoc analysis of the ENZAMET Phase 3 randomised trial (ANZUP 1304)Lin, H.-M., Scheinberg, T., Portman, N., Kim, R.M.N., Mellor, R., Hunyh, K., Faulkner, A.N., Mellett, N.A., Davis, I.D., Martin, A., Sullivan, D., Joshua, A., McJannett, M., Subhash, V., Yip, S., Azad, A.A., Marschner, I.C., North, S.A., McDermott, R.S., Chi, K.N., Stockler, M.R., Sweeney, C.J., Meikle, P.J. and Horvath, L.G. (2025). Association of the circulating lipid panel, PCPro, with clinical outcomes in metastatic hormone-sensitive prostate cancer: post-hoc analysis of the ENZAMET Phase 3 randomised trial (ANZUP 1304). Annals of Oncology, 36 (9), 1068-1077. doi: 10.1016/j.annonc.2025.05.529 |
|
2025 Journal Article Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resistant prostate cancer in ENZA-p (ANZUP1901): a substudy from a multicentre, open-label, randomised, phase 2 trialEmmett, Louise, Papa, Nathan, Subramaniam, Shalini, Crumbaker, Megan, Nguyen, Andrew, Joshua, Anthony M, Sandhu, Shahneen, Weickhardt, Andrew, Lee, Sze-Ting, Ng, Siobhan, Francis, Roslyn J, Goh, Jeffrey C, Pattison, David A, Tan, Thean Hsiang, Kirkwood, Ian D, Ayati, Narjess, Niu, Claire, Hofman, Michael S, Martin, Andrew James, Thomas, Hayley, Davis, Ian D, Stockler, Martin R and Australian and New Zealand Urogenital and Prostate Cancer Trials Group (2025). Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resistant prostate cancer in ENZA-p (ANZUP1901): a substudy from a multicentre, open-label, randomised, phase 2 trial. The Lancet Oncology, 26 (9), 1168-1177. doi: 10.1016/S1470-2045(25)00339-0 |
|
2025 Journal Article INTEGRATE pooled phase II/III results are robust to post-progression switching and winner’s curseSoon, Yu Yang, Sjoquist, Katrin, Marschner, Ian C., Schou, I Manjula, Pavlakis, Nick, Goldstein, David, Shitara, Kohei, Stockler, Martin R., Simes, John and Martin, Andrew J. (2025). INTEGRATE pooled phase II/III results are robust to post-progression switching and winner’s curse. JNCI Cancer Spectrum, 9 (4) pkaf053, 1-7. doi: 10.1093/jncics/pkaf053 |
|
2025 Journal Article Oncologist and general practitioner perspectives of shared care for colorectal cancer survivors: A qualitative studyLisy, Karolina, Tieu, Matthew, Gore, Claire, Schofield, Penelope, Chan, Raymond J., Emery, Jon, Martin, Andrew, De Abreu Lourenco, Richard and Jefford, Michael (2025). Oncologist and general practitioner perspectives of shared care for colorectal cancer survivors: A qualitative study. Psycho-Oncology, 34 (7) e70223, 1-12. doi: 10.1002/pon.70223 |
|
2025 Conference Publication 177 Lu-PSMA-617 with ipilimumab (ipi) and nivolumab (nivo) in metastatic castration-resistant prostate cancer (mCRPC): An investigator-initiated phase 2 trial (EVOLUTION; ANZUP2001)Sandhu, Shahneen, Subramaniam, Shalini, Thomas, Hayley, Tan, Thean Hsiang, Goh, Jeffrey C., Dhiantravan, Nattakorn, Weickhardt, Andrew James, Joshua, Anthony M., Kirkwood, Ian David, Lee, Sze Ting, Gedye, Craig, Nguyen, Andrew, Pattison, David A., Alipour, Ramin, Francis, Roslyn J., Hofman, Michael S., Martin, Andrew James, Stockler, Martin R., Davis, Ian D., Emmett, Louise and The Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) (2025). 177 Lu-PSMA-617 with ipilimumab (ipi) and nivolumab (nivo) in metastatic castration-resistant prostate cancer (mCRPC): An investigator-initiated phase 2 trial (EVOLUTION; ANZUP2001). 2025 ASCO Annual Meeting I, Chicago, IL, United States, 30 May - 3 June 2025. Alexandria, VA, United States: American Society of Clinical Oncology. doi: 10.1200/jco.2025.43.16_suppl.5016 |
|
2025 Conference Publication Association of circulating immune and metabolic markers with clinical outcomes in the ENZAMET trial (ANZUP 1304)Horvath, Lisa, Lin, Hui-Ming, Davis, Ian D., Martin, Andrew James, Yeung, Nicole, Kim, Rachel MN, Portman, Neil, Joshua, Anthony M., McJannett, Margaret Mary, Subhash, Vinod, Yip, Sonia, North, Scott A., McDermott, Raymond S., Chi, Kim N., Stockler, Martin R., Sweeney, Christopher and The Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) (2025). Association of circulating immune and metabolic markers with clinical outcomes in the ENZAMET trial (ANZUP 1304). 2025 ASCO Annual Meeting, Chicago, IL, United States, 30 May - 3 June 2025. Alexandria, VA, United States: American Society of Clinical Oncology. doi: 10.1200/jco.2025.43.16_suppl.5093 |
|
2025 Conference Publication Clonal hematopoiesis (CH) in participants with metastatic castration-resistant prostate cancer (mCRPC) receiving 177 Lu-PSMA-617 or cabazitaxel: An exploratory post-hoc analysis of a randomized phase II trial (TheraP; ANZUP 1603)Munzur, Aslı Doğa, Herberts, Cameron, Kwan, Edmond Michael, Emmett, Louise, Sandhu, Shahneen, Buteau, James Patrick, Iravani, Amir, Joshua, Anthony M., Francis, Roslyn J., Lee, Sze Ting, Scott, Andrew Mark, Martin, Andrew James, Stockler, Martin R., Zhang, Alison Yan, Williams, Scott G., Bacon, Jack V.W., Azad, Arun, Davis, Ian D., Hofman, Michael S., Wyatt, Alexander William and The Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) (2025). Clonal hematopoiesis (CH) in participants with metastatic castration-resistant prostate cancer (mCRPC) receiving 177 Lu-PSMA-617 or cabazitaxel: An exploratory post-hoc analysis of a randomized phase II trial (TheraP; ANZUP 1603). 2025 ASCO Annual Meeting I, Chicago, IL, United States, 30 May - 3 June 2025. Alexandria, VA, United States: American Society of Clinical Oncology. doi: 10.1200/jco.2025.43.16_suppl.5020 |
|
2025 Conference Publication Predictive and prognostic value of baseline PSMA-PET total tumor volume and SUV mean within ENZA-p, a randomized phase II trial of enzalutamide versus enzalutamide plus [ 177 Lu] Lu-PSMA-617 (ANZUP1901)Emmett, Louise, Papa, Nathan, Subramaniam, Shalini, Crumbaker, Megan, Joshua, Anthony M., Nguyen, Andrew, Weickhardt, Andrew James, Lee, Sze Ting, Ng, Siobhan, Francis, Roslyn J., Goh, Jeffrey C., Pattison, David A., Tan, Thean Hsiang, Kirkwood, Ian David, Hofman, Michael S., Sandhu, Shahneen, Martin, Andrew James, Thomas, Hayley, Davis, Ian D., Stockler, Martin R. and The Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) (2025). Predictive and prognostic value of baseline PSMA-PET total tumor volume and SUV mean within ENZA-p, a randomized phase II trial of enzalutamide versus enzalutamide plus [ 177 Lu] Lu-PSMA-617 (ANZUP1901). 2025 ASCO Annual Meeting, Chicago, IL, United States, 30 May - 3 June 2025. Alexandria, VA, United States: American Society of Clinical Oncology. doi: 10.1200/jco.2025.43.16_suppl.5011 |
